ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.150,71
-0,10%
S&P 500
5.303,27
0,12%
US Dollar vs BRL
5,1047
-0,50%
Bitcoin
66.803,78
2,40%
Brent Oil
83,76
0,67%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. OptiNose Inc (OPTN)

  7. OptiNose Inc (OPTN) Notícias

OPTN

OptiNose (OPTN)

OptiNose Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:OPTN
DataHoraFonteTítuloCódigoCompanhia
17/05/202413:00GlobeNewswire Inc.Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQNASDAQ:OPTNOptiNose Inc
14/05/202410:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:OPTNOptiNose Inc
14/05/202408:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OPTNOptiNose Inc
14/05/202408:00GlobeNewswire Inc.Optinose Reports First Quarter 2024 Financial Results and Recent Operational HighlightsNASDAQ:OPTNOptiNose Inc
10/05/202415:56GlobeNewswire Inc.Optinose Announces Reporting Date for First Quarter 2024 Financial ResultsNASDAQ:OPTNOptiNose Inc
09/05/202408:09Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:OPTNOptiNose Inc
09/05/202408:00GlobeNewswire Inc.Optinose Announces $55 Million Registered Direct OfferingNASDAQ:OPTNOptiNose Inc
25/04/202408:00GlobeNewswire Inc.Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 millionNASDAQ:OPTNOptiNose Inc
04/04/202417:01GlobeNewswire Inc.Optinose to Present at the Needham Virtual Healthcare ConferenceNASDAQ:OPTNOptiNose Inc
15/03/202416:34GlobeNewswire Inc.XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal PolypsNASDAQ:OPTNOptiNose Inc
07/03/202418:32Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:OPTNOptiNose Inc
07/03/202409:01Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:OPTNOptiNose Inc
07/03/202409:00GlobeNewswire Inc.Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational HighlightsNASDAQ:OPTNOptiNose Inc
29/02/202418:40GlobeNewswire Inc.Optinose Announces Reporting Date for Fourth Quarter 2023 Financial ResultsNASDAQ:OPTNOptiNose Inc
29/02/202418:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OPTNOptiNose Inc
22/02/202418:28Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:OPTNOptiNose Inc
18/01/202414:00GlobeNewswire Inc.Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In PracticeNASDAQ:OPTNOptiNose Inc
06/12/202310:48Dow Jones NewsOptinose Shares Slide Premarket as FDA Extends Xhance ReviewNASDAQ:OPTNOptiNose Inc
06/12/202309:00GlobeNewswire Inc.Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCENASDAQ:OPTNOptiNose Inc
22/11/202311:00GlobeNewswire Inc.Optinose to Present at the 35th Annual Piper Sandler Healthcare ConferenceNASDAQ:OPTNOptiNose Inc
09/11/202309:00GlobeNewswire Inc.Optinose Reports Third Quarter 2023 Financial Results and Operational UpdatesNASDAQ:OPTNOptiNose Inc
27/10/202309:00GlobeNewswire Inc.Optinose Announces Reporting Date for Third Quarter 2023 Financial ResultsNASDAQ:OPTNOptiNose Inc
22/09/202310:01GlobeNewswire Inc.Optinose to Present at the 2023 Cantor Global Healthcare ConferenceNASDAQ:OPTNOptiNose Inc
18/08/202301:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:OPTNOptiNose Inc
10/08/202317:05Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:OPTNOptiNose Inc
10/08/202308:00GlobeNewswire Inc.Optinose Reports Second Quarter 2023 Financial Results and Operational UpdatesNASDAQ:OPTNOptiNose Inc
27/07/202308:00GlobeNewswire Inc.Optinose Announces Preliminary Second Quarter 2023 XHANCE Net Revenue of $19.5 MillionNASDAQ:OPTNOptiNose Inc
20/06/202314:05Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OPTNOptiNose Inc
16/06/202317:08GlobeNewswire Inc.Optinose Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:OPTNOptiNose Inc
02/06/202314:00GlobeNewswire Inc.Optinose to Present at the Jefferies Healthcare ConferenceNASDAQ:OPTNOptiNose Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:OPTN

Seu Histórico Recente

LSE
DGRA
Wt Us Grw
EU
B276
L Etat Belge De Belgisch...
BIT
WSREUA
UBS Lux Fund Solutio MSC...
COIN
WOOPETH
Woonkly Power
NASDAQ
PTIXW
Protagenic Therapeutics
COIN
QCHUSD
QChi
USOTC
IWTNF
Iwatani (PK)
LSE
JREI
Jpm Jpn Etf D
ASX
BZM
COIN
PRXBTC
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados